Is Gossamer Bio Inc (GOSS) overvalued? · rev $114.7M
Gossamer Bio Inc (GOSS) is a biotechnology company listed on US.
This page asks whether Gossamer Bio Inc (GOSS) looks expensive on cached numbers — not a short thesis.
Latest reported GOSS revenue for 2024-12-31 was $114.7M. Net income was -$56.5M. GOSS currently screens at market cap $47.0M.
GOSS currently screens at market cap $47.0M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next GOSS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the GOSS stock page for the full model, not this heading.
Not investment advice.